# CHINA BIOTECH SERVICES HOLDINGS LIMITED
# 中國生物科技服務控股有限公司

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock code: 8037)**

## VOLUNTARY ANNOUNCEMENT
## MASTER COLLABORATION AGREEMENT WITH STELLA PHARMA CORPORATION IN RELATION TO COMMERCIALISATION OF BNCT DRUG

Building on the ongoing collaboration with Stella Pharma on Steboronine® (the world's first approved BNCT drug), the Group has entered into the Master Collaboration Agreement with Stella Pharma on 11 August 2026 to jointly advance the development and commercialisation of Steboronine® in the PRC.

The collaboration synergises with the Group's flagship Pengbo Hainan BNCT hospital, marking a significant strategic move by the Group to introduce advanced BNCT technology to the PRC market. This will further consolidate and develop the Group's business in PRC, accelerate the Group's layout in the upstream BNCT industry and strengthen its future competitiveness.

This announcement is made by China Biotech Services Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep the shareholders and potential investors of the Company informed of the latest business development of the Group.

**Background**

Reference is made to the voluntary announcement of the Company dated 8 May 2025 in relation to a memorandum of understanding signed with STELLA PHARMA CORPORATION ("**Stella Pharma**") regarding the intended further collaboration in the sale and production of Steboronine® (the world's first approved boron neutron capture therapy (BNCT) drug). As disclosed in the said announcement, the further collaboration contemplates, among other things, the signing of a master collaboration agreement in relation to the commercialisation of Steboronine® in the People's Republic of China (the "**PRC**") as the next stage of collaboration between the parties.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the ongoing collaboration with Stella Pharma has entered a new phase. On 11 August 2026, the Company, Pengbo (Hainan) Medical Technology Co., Ltd.* (鵬博(海南)硼中子醫療科技有限公司) ("**Pengbo (Hainan)**") and Stella Pharma entered into a legally binding master collaboration agreement in relation to the development and commercialisation of Steboronine® in the PRC (the "**Master Collaboration Agreement**").

**Master Collaboration Agreement**

The collaboration under the Master Collaboration Agreement is structured in two stages, namely the development stage and the commercialisation stage.

*1. Development Stage*

**NMPA Approval:** The purpose is for Stella Pharma to obtain and maintain the marketing approval of Steboronine® for head and neck cancers (and for Meningioma upon Stella Pharma obtaining marketing and manufacturing approval from the Japanese government for Steboronine® in the field of Meningioma) in the PRC by the Chinese National Medical Products Administration (NMPA) ("**NMPA Approval**") as soon as practically possible, leveraging Real-World Data (RWD), Real-World Evidence (RWE), and Real-World Studies (RWS) generated by the Group. The parties shall collaborate on all clinical and non-clinical activities to develop Steboronine® and obtain and maintain NMPA Approval.

**Exclusive Development License:** Stella Pharma has granted the Group an exclusive, non-transferable, non-sublicensable, royalty-free license under Stella Pharma's initial data package to develop Steboronine® in the PRC (excluding manufacturing activities). The Group shall submit the regulatory filings to NMPA as an application agent on behalf of Stella Pharma to obtain NMPA Approval.

**Exclusivity:** During the development stage, Stella Pharma shall not appoint any third party other than the Group as a domestic agent and as a general import agent for Steboronine® in the PRC.

**Next Generation Product:** If, during the term of the Master Collaboration Agreement, Stella Pharma obtains NMPA Approval and initiates clinical trials of the next generation of Steboronine®, the Group will have a 3-month right of first refusal to commercialise the next-generation product in the PRC on terms no less favourable than those offered to or proposed by any third party.

*2. Commercialisation Stage*

**Exclusive Domestic Agent:** Upon Stella Pharma obtaining NMPA Approval, Pengbo (Hainan) shall automatically become the exclusive domestic agent for Steboronine® in the PRC. Stella Pharma as the holder of NMPA Approval and Pengbo (Hainan) as exclusive domestic agent shall cooperate to establish and implement the post-approval regulatory arrangements required under the applicable law.

**Exclusive General Import Agent/Distributor:** Upon Stella Pharma obtaining NMPA Approval, the Company (or its designated controlled entity) shall automatically become the exclusive general import agent/distributor for Steboronine® in the PRC. Stella Pharma shall supply Steboronine® for Pengbo (Hainan), the Company or its designated entity to distribute and sell Steboronine® in the PRC. The exclusive distribution right is for an initial period of 10 years from the date of NMPA Approval, which is automatically extendable for successive 5-year periods subject to the achievement of certain purchase targets.

***Term***

The Master Collaboration Agreement shall be effective from the date thereof until the expiration of 10 years after Stella Pharma obtains NMPA Approval provided that if the exclusive distribution period is extended, the term of the Master Collaboration Agreement shall be automatically extended accordingly. If Stella Pharma fails to obtain NMPA Approval within 10 years from the date of the Master Collaboration Agreement, the term shall expire immediately upon the end of such 10 years.

**Reasons for and Benefits of the Master Collaboration Agreement**

The Pengbo Hainan BNCT hospital, being the Group's flagship project located in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, the PRC, commenced trial operations in February 2026, and began patient treatment for the first time in March 2026 with dozens of treatments completed to date. The Group has introduced Steboronine® at the hospital to provide safe and precise BNCT services to cancer patients.

The collaboration under the Master Collaboration Agreement represents a monumental step in the Group's strategic initiative to bring advanced BNCT cancer treatments to the PRC market. The Group and Stella Pharma will jointly advance the regulatory approval process of Steboronine® and collaborate on its commercialisation in the PRC. This will accelerate the Group's upstream positioning in the BNCT industry and strengthen its future competitiveness.

By order of the Board
**China Biotech Services Holdings Limited**
**Liu Xiaolin**
*Chairman and Executive Director*

* *for identification purposes only*

Hong Kong, 12 August 2026

*As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Liu Xiaolin (Chairman), Dr. Huang Song and Dr. Yin Ye; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Guo Yuantao and Dr. Zhang Xiao.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the "Latest Listed Company Information" page of the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk. com.*